Current options for the treatment of Paget’s disease of the bone
Daniela Merlotti, Luigi Gennari, Giuseppe Martini, Ranuccio NutiDepartment of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, ItalyAbstract: Paget’s disease of bone (PDB) is a chronic bone remodeling disorder characterized by increased oste...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/179fc24e58804a3f81759e11b5ebfdac |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:179fc24e58804a3f81759e11b5ebfdac |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:179fc24e58804a3f81759e11b5ebfdac2021-12-02T01:34:00ZCurrent options for the treatment of Paget’s disease of the bone1179-156Xhttps://doaj.org/article/179fc24e58804a3f81759e11b5ebfdac2009-07-01T00:00:00Zhttp://www.dovepress.com/current-options-for-the-treatment-of-pagetrsquos-disease-of-the-bone-a3373https://doaj.org/toc/1179-156XDaniela Merlotti, Luigi Gennari, Giuseppe Martini, Ranuccio NutiDepartment of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, ItalyAbstract: Paget’s disease of bone (PDB) is a chronic bone remodeling disorder characterized by increased osteoclast-mediated bone resorption, with subsequent compensatory increases in new bone formation, resulting in a disorganized mosaic of woven and lamellar bone at affected skeletal sites. This disease is most often asymptomatic but can be associated with bone pain or deformity, fractures, secondary arthritis, neurological complications, deafness, contributing to substantial morbidity and reduced quality of life. Neoplastic degeneration of pagetic bone is a relatively rare event, occurring with an incidence of less than 1%, but has a grave prognosis. Specific therapy for PDB is aimed at decreasing the abnormal bone turnover and bisphosphonates are currently considered the treatment of choice. These treatments are associated with a reduction in plasma alkaline phosphatase (ALP) activity and an improvement in radiological and scintigraphic appearance and with a reduction in bone pain and bone deformity, Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more effective and convenient management of this debilitating disorder.Keywords: Paget’s disease of bone, bisphosphonates, aminobisphosphonates, bone remodeling Daniela MerlottiLuigi GennariGiuseppe Martiniet alDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2009, Iss default, Pp 107-120 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diseases of the musculoskeletal system RC925-935 |
| spellingShingle |
Diseases of the musculoskeletal system RC925-935 Daniela Merlotti Luigi Gennari Giuseppe Martini et al Current options for the treatment of Paget’s disease of the bone |
| description |
Daniela Merlotti, Luigi Gennari, Giuseppe Martini, Ranuccio NutiDepartment of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, ItalyAbstract: Paget’s disease of bone (PDB) is a chronic bone remodeling disorder characterized by increased osteoclast-mediated bone resorption, with subsequent compensatory increases in new bone formation, resulting in a disorganized mosaic of woven and lamellar bone at affected skeletal sites. This disease is most often asymptomatic but can be associated with bone pain or deformity, fractures, secondary arthritis, neurological complications, deafness, contributing to substantial morbidity and reduced quality of life. Neoplastic degeneration of pagetic bone is a relatively rare event, occurring with an incidence of less than 1%, but has a grave prognosis. Specific therapy for PDB is aimed at decreasing the abnormal bone turnover and bisphosphonates are currently considered the treatment of choice. These treatments are associated with a reduction in plasma alkaline phosphatase (ALP) activity and an improvement in radiological and scintigraphic appearance and with a reduction in bone pain and bone deformity, Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more effective and convenient management of this debilitating disorder.Keywords: Paget’s disease of bone, bisphosphonates, aminobisphosphonates, bone remodeling |
| format |
article |
| author |
Daniela Merlotti Luigi Gennari Giuseppe Martini et al |
| author_facet |
Daniela Merlotti Luigi Gennari Giuseppe Martini et al |
| author_sort |
Daniela Merlotti |
| title |
Current options for the treatment of Paget’s disease of the bone |
| title_short |
Current options for the treatment of Paget’s disease of the bone |
| title_full |
Current options for the treatment of Paget’s disease of the bone |
| title_fullStr |
Current options for the treatment of Paget’s disease of the bone |
| title_full_unstemmed |
Current options for the treatment of Paget’s disease of the bone |
| title_sort |
current options for the treatment of paget’s disease of the bone |
| publisher |
Dove Medical Press |
| publishDate |
2009 |
| url |
https://doaj.org/article/179fc24e58804a3f81759e11b5ebfdac |
| work_keys_str_mv |
AT danielamerlotti currentoptionsforthetreatmentofpagetamprsquosdiseaseofthebone AT luigigennari currentoptionsforthetreatmentofpagetamprsquosdiseaseofthebone AT giuseppemartini currentoptionsforthetreatmentofpagetamprsquosdiseaseofthebone AT etal currentoptionsforthetreatmentofpagetamprsquosdiseaseofthebone |
| _version_ |
1718403001296617472 |